Skip to main content
Erschienen in: European Journal of Pediatrics 2/2005

01.02.2005 | Original Paper

Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease)

verfasst von: Sophie Dupuis-Girod, Véronique Akkari, Cécile Ged, Claire Galambrun, Kamila Kebaïli, Jean-Charles Deybach, Alain Claudy, Lucette Geburher, Noël Philippe, Hubert de Verneuil, Yves Bertrand

Erschienen in: European Journal of Pediatrics | Ausgabe 2/2005

Einloggen, um Zugang zu erhalten

Abstract

Congenital erythropoietic porphyria (CEP; Günther disease; OMIM 263700) is a rare autosomal recessive disorder caused by a deficiency of uroporphyrinogen III synthase (UROS). The deficiency of this enzyme is associated with lifelong overproduction of series I porphyrins which circulate and are deposited in many tissues, causing light-sensitisation and severe damage to skin beginning in childhood. Blistering and scarring of exposed areas may lead to mutilating deformities. We describe two cases: a 4-year-old boy and his first cousin who were cured of CEP by matched unrelated donor bone marrow transplants. Both are alive and disease-free 3 and 2 years post-transplant, respectively. Cutaneous lesions improved dramatically. The correction of the enzyme deficiency was confirmed by measuring erythrocyte UROS activity and urinary porphyrin excretion. Chimerism was complete for both children. Both patients were homoallelic for a novel mutation of the UROS gene, the missense mutation A69T. Conclusion:Considering the severity of the disease, if HLA-matched sibling donor is not available, haematopoietic stem cell transplantation using a matched unrelated donor should be strongly considered for treating congenital erythropoietic porphyria since this is currently the only known curative therapy.
Literatur
1.
Zurück zum Zitat Anderson KE, Sassa S, Bishop DF, Desnick RJ (2001) Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR Beaudet A, Valle D, Sly WS (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 2961–3062 Anderson KE, Sassa S, Bishop DF, Desnick RJ (2001) Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR Beaudet A, Valle D, Sly WS (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 2961–3062
2.
Zurück zum Zitat Desnick RJ, Astrin KH (2002) Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol 117: 779–795CrossRefPubMed Desnick RJ, Astrin KH (2002) Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol 117: 779–795CrossRefPubMed
3.
Zurück zum Zitat Fontanellas A, Bensidhoum M, Enriquez de Salamanca R, Moruno Tirado A, de Verneuil H, Ged C (1996) A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Eur J Hum Genet 4: 274–282PubMed Fontanellas A, Bensidhoum M, Enriquez de Salamanca R, Moruno Tirado A, de Verneuil H, Ged C (1996) A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Eur J Hum Genet 4: 274–282PubMed
4.
Zurück zum Zitat Fontanellas A, Mendez M, Mazurier F, Cario-Andre M, Navarro S, Ged C, Taine L, Geronimi F, Richard E, Moreau-Gaudry F, Enriquez De Salamanca R, de Verneuil H (2001) Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells. Gene Ther 8: 618–626CrossRefPubMed Fontanellas A, Mendez M, Mazurier F, Cario-Andre M, Navarro S, Ged C, Taine L, Geronimi F, Richard E, Moreau-Gaudry F, Enriquez De Salamanca R, de Verneuil H (2001) Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells. Gene Ther 8: 618–626CrossRefPubMed
5.
Zurück zum Zitat Frank J, Wang X, Lam HM, Aita VM, Jugert FK, Goerz G, Merk HF, Poh-Fitzpatrick MB, Christiano AM (1998) C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Ann Hum Genet 62: 225–230CrossRefPubMed Frank J, Wang X, Lam HM, Aita VM, Jugert FK, Goerz G, Merk HF, Poh-Fitzpatrick MB, Christiano AM (1998) C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Ann Hum Genet 62: 225–230CrossRefPubMed
6.
Zurück zum Zitat Fritsch C, Bolsen K, Ruzicka T, Goerz G (1997) Congenital erythropoietic porphyria. J Am Acad Dermatol 36: 594–610PubMed Fritsch C, Bolsen K, Ruzicka T, Goerz G (1997) Congenital erythropoietic porphyria. J Am Acad Dermatol 36: 594–610PubMed
7.
Zurück zum Zitat Geronimi F, Richard E, Lamrissi-Garcia I, Lalanne M, Ged C, Redonnet-Vernhet I, Moreau-Gaudry F, de Verneuil H (2003) Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells. J Mol Med 81: 310–320PubMed Geronimi F, Richard E, Lamrissi-Garcia I, Lalanne M, Ged C, Redonnet-Vernhet I, Moreau-Gaudry F, de Verneuil H (2003) Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells. J Mol Med 81: 310–320PubMed
8.
Zurück zum Zitat Harada FA, Shwayder TA, Desnick RJ, Lim HW (2001) Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol 45: 279–282CrossRefPubMed Harada FA, Shwayder TA, Desnick RJ, Lim HW (2001) Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol 45: 279–282CrossRefPubMed
9.
Zurück zum Zitat Kauffman L, Evans DI, Stevens RF, Weinkove C (1991) Bone-marrow transplantation for congenital erythropoietic porphyria. Lancet 337: 1510–1511CrossRefPubMed Kauffman L, Evans DI, Stevens RF, Weinkove C (1991) Bone-marrow transplantation for congenital erythropoietic porphyria. Lancet 337: 1510–1511CrossRefPubMed
10.
Zurück zum Zitat Lagarde C, Hamel-Teillac D, De Prost Y, Blanche S, Thomas C, Fischer A, Nordmann Y, Ged C, De Verneuil H (1998) Allogeneic bone marrow transplantation in congenital erythropoietic porphyria. Gunther’s disease. Ann Dermatol Venereol 125: 114–117PubMed Lagarde C, Hamel-Teillac D, De Prost Y, Blanche S, Thomas C, Fischer A, Nordmann Y, Ged C, De Verneuil H (1998) Allogeneic bone marrow transplantation in congenital erythropoietic porphyria. Gunther’s disease. Ann Dermatol Venereol 125: 114–117PubMed
11.
Zurück zum Zitat Mazurier F, Geronimi F, Lamrissi-Garcia I, Morel C, Richard E, Ged C, Fontanellas A, Moreau-Gaudry F, Morey M, de Verneuil H (2001) Correction of deficient CD34+ cells from peripheral blood after mobilization in a patient with congenital erythropoietic porphyria. Mol Ther 3: 411–417CrossRefPubMed Mazurier F, Geronimi F, Lamrissi-Garcia I, Morel C, Richard E, Ged C, Fontanellas A, Moreau-Gaudry F, Morey M, de Verneuil H (2001) Correction of deficient CD34+ cells from peripheral blood after mobilization in a patient with congenital erythropoietic porphyria. Mol Ther 3: 411–417CrossRefPubMed
12.
Zurück zum Zitat Moreau-Gaudry F, Ged C, de Verneuil H (1996) Gene therapy for erythropoietic porphyrias. Gene Ther 3: 843–844PubMed Moreau-Gaudry F, Ged C, de Verneuil H (1996) Gene therapy for erythropoietic porphyrias. Gene Ther 3: 843–844PubMed
13.
Zurück zum Zitat Richard E, Mendez M, Mazurier F, Morel C, Costet P, Xia P, Fontanellas A, Geronimi F, Cario-Andre M, Taine L, Ged C, Malik P, de Verneuil H, Moreau-Gaudry F (2001) Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Mol Ther 4: 331–338CrossRefPubMed Richard E, Mendez M, Mazurier F, Morel C, Costet P, Xia P, Fontanellas A, Geronimi F, Cario-Andre M, Taine L, Ged C, Malik P, de Verneuil H, Moreau-Gaudry F (2001) Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Mol Ther 4: 331–338CrossRefPubMed
14.
Zurück zum Zitat Shady AA, Colby BR, Cunha LF, Astrin KH, Bishop DF, Desnick RJ (2002) Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene. Br J Haematol 117: 980–987CrossRefPubMed Shady AA, Colby BR, Cunha LF, Astrin KH, Bishop DF, Desnick RJ (2002) Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene. Br J Haematol 117: 980–987CrossRefPubMed
15.
Zurück zum Zitat Shaw PH, Mancini AJ, McConnell JP, Brown D, Kletzel M (2001) Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant 27: 101–115CrossRefPubMed Shaw PH, Mancini AJ, McConnell JP, Brown D, Kletzel M (2001) Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant 27: 101–115CrossRefPubMed
16.
Zurück zum Zitat Tezcan I, Xu W, Gurgey A, Tuncer M, Cetin M, Oner C, Yetgin S, Ersoy F, Aizencang G, Astrin KH, Desnick RJ (1998) Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation. Blood 92: 4053–4058PubMed Tezcan I, Xu W, Gurgey A, Tuncer M, Cetin M, Oner C, Yetgin S, Ersoy F, Aizencang G, Astrin KH, Desnick RJ (1998) Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation. Blood 92: 4053–4058PubMed
17.
Zurück zum Zitat Thomas C, Ged C, Nordmann Y, de Verneuil H, Pellier I, Fischer A, Blanche S (1996) Correction of congenital erythropoietic porphyria by bone marrow transplantation. J Pediatr 129: 453–456PubMed Thomas C, Ged C, Nordmann Y, de Verneuil H, Pellier I, Fischer A, Blanche S (1996) Correction of congenital erythropoietic porphyria by bone marrow transplantation. J Pediatr 129: 453–456PubMed
18.
Zurück zum Zitat de Verneuil H, Ged C, Moreau-Gaudry F (2003) Congenital erythropoietic porphyria. In: Kadish KM GR, Smith K (eds) Porphyria handbook II, vol 14. Academic Press, New York, pp 43–63 de Verneuil H, Ged C, Moreau-Gaudry F (2003) Congenital erythropoietic porphyria. In: Kadish KM GR, Smith K (eds) Porphyria handbook II, vol 14. Academic Press, New York, pp 43–63
19.
Zurück zum Zitat Zix-Kieffer I, Langer B, Eyer D, Acar G, Racadot E, Schlaeder G, Oberlin F, Lutz P (1996) Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther’s disease). Bone Marrow Transplant 18: 217–220PubMed Zix-Kieffer I, Langer B, Eyer D, Acar G, Racadot E, Schlaeder G, Oberlin F, Lutz P (1996) Successful cord blood stem cell transplantation for congenital erythropoietic porphyria (Gunther’s disease). Bone Marrow Transplant 18: 217–220PubMed
Metadaten
Titel
Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease)
verfasst von
Sophie Dupuis-Girod
Véronique Akkari
Cécile Ged
Claire Galambrun
Kamila Kebaïli
Jean-Charles Deybach
Alain Claudy
Lucette Geburher
Noël Philippe
Hubert de Verneuil
Yves Bertrand
Publikationsdatum
01.02.2005
Verlag
Springer-Verlag
Erschienen in
European Journal of Pediatrics / Ausgabe 2/2005
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-004-1575-x

Weitere Artikel der Ausgabe 2/2005

European Journal of Pediatrics 2/2005 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.